# Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

> **NCT02760407** · PHASE3 · COMPLETED · sponsor: **R-Pharm International, LLC** · enrollment: 1648 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Olokizumab 64mg q4w
- **DRUG:** Olokizumab 64mg q2w
- **DRUG:** Adalimumab 40mg q2w
- **DRUG:** Placebo q2w

## Key facts

- **NCT ID:** NCT02760407
- **Lead sponsor:** R-Pharm International, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-06
- **Primary completion:** 2019-08-02
- **Final completion:** 2019-11-05
- **Target enrollment:** 1648 (ACTUAL)
- **Last updated:** 2023-09-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02760407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02760407, "Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02760407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*